TheraVet announced the launch of BIOCERA-VET Equine in countries already covered by the Company. After being assessed by equine vets in orthopedic and dental applications over the past 12 months, BIOCERA-VET is now available on the market with 2 additional references (3cc and 6cc) specifically adapted in terms of volume and devices for equine applications. BIOCERA-VET has an exclusive positioning in the treatment of subchondral bone cysts, thanks to the properties - that only BIOCERA-VET offers on the market - required for minimally invasive ementoplasty (high injectability, long workability, high radiopacity, high cohesiveness and fast self-setting).

The subchondral bone cysts affect 25% of yearlings (horses in their second year), representing 200,000 horses in Europe and in the United States and common cause of lameness and reduced performance of young equine athletes. BIOCERA-VET will also be used as innovative treatment in dental applications and oral/maxillofacial surgery (damage to the alveolar bone, delayed alveolar granulation or orosinus fistulation, common complications after tooth extraction).